BIOCHEMISTRY, BIOMEDICINE & PHARMACEUTICS

BLINCYTO® (blinatumomab): Bispecific CD19-Directed CD3 T-cell Engager   BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adults and children with:  • B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. This indication is approved under accelerated approval based on MRD response rate and hematological relapse-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.  • Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).  Mechanism of Action: Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T cells. It activates endogenous T cells by connecting CD3 in the T-cell receptor (TCR) c...

HPN536 is a novel, MSLN targeted, trispecific, T-cell–activating protein construct that can potently redirect T cells to lyse tumor cells and was remarkably well tolerated in nonhuman primates at single doses up to 10 mg/kg, which is far above the expected therapeutic dose level. Harpoon Therapeutics are conduction "A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression Who Have Failed Standard Available Therapy" The objective of the trial is to -assess safety and tolerability at increasing dose levels  - Pharmacokinetic and pharmacodynamic data  ‐ Evaluate preliminary anti-tumor activity Dosing has occurred across 10 fixed-dose cohorts of 6 to 560ng/kg and three step dose cohort up to 1200ng/kg, with total enrollment of 60 patients. Tumor types treated include late-stage ovarian (47%), pancreatic (40%) and peritoneal ...

HPN424 is a prostate-specific membrane antigen (PSMA)- targeting T cell engager, engineered with three binding domains: • PSMA (for tumor binding) • Albumin (for half-life extension) • CD3 (for T cell engagement) HPN424 is constructed as a small, globular protein (~50kDa) to enable efficient solid tumor penetration with prolonged half-life and excellent stability. HPN424 is designed to bind monovalently to CD3 and PSMA, minimizing non-specific T-cell activation. Harpoon Therapeutics is currently conducting a "Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients With Advanced Prostate Cancer Refractory to Androgen Therapy" As of May 31, 2021, the data cutoff date for the Company’s HPN424 presentation, the Company updated the ASCO interim data to describe newly enrolled patients and additional follow-up on existing patients already enrolled in the 300 ng/kg step dose cohort. The...

  About Harpoon Therapeutics Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC ® ) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets D...